Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting
Tuesday, November 04, 2025
Sumitomo Pharma America, Inc. (SMPA) today announced its plans to unveil new investigational clinical data at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, set to take place in Orlando, Florida, from December 6-9, 2025. These presentations center on developments in the clinical pipeline for the company’s novel oral small molecule therapeutics in hematologic malignancies, marking an important milestone in the company’s effort to address unmet medical needs among patients in Asia and globally.
The new data includes results from ongoing Phase 1/2 studies evaluating the safety, tolerability, and early clinical activity of enzomenib (DSP-5336), a menin inhibitor, and nuvisertib (TP-3654), a selective PIM1 kinase inhibitor. Specifically, Sumitomo will present data on enzomenib as both a monotherapy and in combination with venetoclax and azacitidine in relapsed/refractory acute myeloid leukemia (AML). The preliminary results are promising, indicating that enzomenib demonstrates clinical activity across a spectrum of potentially therapeutic doses. Early signals from the combination studies suggest that the therapy is well tolerated and could benefit patients with difficult-to-treat forms of AML, including those with genetic subtypes such as KMT2A-rearranged and NPM1-mutated leukemia.
For nuvisertib, the company will share preliminary findings from monotherapy and combination studies in relapsed/refractory myelofibrosis. Early data show encouraging clinical activity for nuvisertib, especially when combined with momelotinib, a therapy for myelofibrosis recently approved in several Asian markets. The combination has demonstrated a favorable safety profile, supporting further development in broader hematologic populations. Monotherapy data indicate that nuvisertib is well tolerated, with desirable cytokine modulation correlating with clinical response, presenting another avenue for tackling difficult hematologic conditions.
These advancements are especially relevant for the Asia-Pacific region, where the burden of hematologic cancers remains high, and access to innovative therapies is a critical issue. Regulatory enthusiasm is reflected by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), which granted Orphan Drug Designation for enzomenib targeting relapsed/refractory AML with MLLr or NPM1m in September 2024, following similar Fast Track and Orphan Drug Designations from the US FDA in recent years. These designations signal strong confidence in enzomenib’s potential as a differentiated therapy for previously underserved patients in the region.
SMPA’s Chief Medical Officer, Oncology, Jatin Shah, M.D., stated, “Patients living with relapsed/refractory AML or MF desperately need effective therapies to overcome the poor prognoses typically associated with these cancers. The clinical data are highly compelling, especially for patients with particularly challenging forms of acute leukemia, including those with KMT2A-rearranged and NPM1-mutated subtypes. Based on this progress, we look forward to sharing more comprehensive data further supporting the development of enzomenib and nuvisertib at the upcoming meeting in December and remain committed to advancing both of these programs.”
From a B2B perspective, SMPA’s announcements are of key importance to CROs, pharma partners, regulatory strategists, and investors across Asia. The presentation of actionable new data, particularly in the context of strategic regulatory progress, highlights accelerating cycles of innovation and collaboration between US and Asia-based pharma entities. The clinical momentum behind menin inhibitors and PIM1 kinase inhibitors reaffirms Asia’s role as a critical region for global drug development, especially in areas where patient populations have high unmet needs and access to new therapeutics remains uneven. As biotech and drug manufacturing ecosystems in markets like Japan, South Korea, and China seek partnerships around advanced molecules and rare disease management, developments from SMPA could foster further clinical collaborations, manufacturing investments, and regulatory approvals in Asia within the next year.
The disclosed investigational results, including the ongoing dialogue with regulatory authorities and global conference participation, reflect Sumitomo Pharma America’s commitment to evidence-driven expansion of its hematologic pipeline in Asia. These clinical programs, underpinned by regulatory support and strategic dissemination of data, underscore the company’s objective to move therapeutics for refractory AML and myelofibrosis closer to clinical utilization, potentially transforming treatment paradigms for challenging blood malignancies in both mature and emerging Asian markets.
